Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary p110α (PIK3CA) is the most frequently mutated kinase in human cancer, and numerous drugs targeting this kinase are currently in pre-clinical development or early stage clinical trials. Clinical resistance to protein kinase inhibitors frequently results from point mutations that block drug binding; similar mutations in p110α are likely, but currently none have been reported. Using a S. cerevisiae screen against a structurally diverse panel of PI3K inhibitors, we have identified a potential hotspot for resistance mutations (I800), a drug-sensitizing mutation (L814C), and a surprising lack of resistance mutations at the “gatekeeper” residue. Our analysis further reveals that clinical resistance to these drugs may be attenuated by using multi-targeted inhibitors that simultaneously inhibit additional PI3K pathway members. Significance Point mutations that block drug binding are likely to be a major mechanism of clinical resistance to PI3K-targeted cancer therapy. Here we report resistance mutations in the oncogenic PI3K isoform p110α, as well as a drug-sensitizing mutation that will be useful for chemical genetic studies. This study anticipates p110α mutations that are likely to emerge against PI3K-targeted drugs, and identifies inhibitor classes that can overcome these resistance mutations. Our experiments in mammalian cells show that multi-targeted inhibitors with additional PI3K pathway targets are less susceptible to drug resistance than selective PI3K inhibitors. The screening protocol described here is applicable to several other drug targets that inhibit S. cerevisiae growth in addition to p110α.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“…recruits downstream signaling proteins such as Akt to the plasma membrane, leading to increased growth, proliferation, motility, and cell survival (Cantley, 2002). p110 a has attracted considerable interest as a drug target (Hennessy et al., 2005; Luo et al., 2003; Stephens et al., 2005) since…”
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“…of resistance to protein kinase inhibitors in cancer therapy is point mutation of the target kinase that blocks drug binding (Daub et al., 2004; Gorre et al., 2001; Mahon et al., 2000; Shah et al., 2002; Shah and Sawyers, 2003), and mutation at one position in particular is frequently observed…”
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 2×
“…members, including receptor tyrosine kinases (RTKs), Ras, PTEN, and Akt, are frequently mutated instead (Brugge et al., 2007; Cully et al., 2006; Shaw and Cantley, 2006), high-lighting the critical role that PI3K signaling plays in oncogenesis and tumor maintenance (Gupta et al., 2007; Lim and…”
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Self-citationPten Regulates Neuronal Arborization and Social Interaction in Mice
Kwon, C.-H., Luikart, B. W., Powell, C. M., Zhou, J., Matheny, S. A., Zhang, W., Li, Y., Baker, S. J., & Parada, L. F. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.023 · Cited by 970
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Cited by
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis
Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S.-W., & Cravatt, B. F. (2010) · Cell · doi:10.1016/j.cell.2009.11.027 · Cited by 1,002
“…the action of phosphatidylinositol-3-kinase and activates protein kinase B/Akt to promote cell proliferation and survival (Yuan and Cantley, 2008; Zunder et al., 2008); (2) lysophosphatidic acid (LPA), which signals through a family of G protein-coupled receptors to stimulate cancer…”
BackgroundChappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids
Zaidi, N., Lupien, L., Kuemmerle, N. B., Kinlaw, W. B., Swinnen, J. V., & Smans, K. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.08.005 · Cited by 477
Metadata
- Authors
- Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B., & Shokat, K. M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 14
- Issue
- 2
- Pages
- 180-192
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2058843172
- Cited by
- 95
- References
- 7
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.